Every 10-Q that Greenwich Lifesciences Inc (GLSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GLSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLSI filings page.
Greenwich LifeSciences, Inc. reported unaudited results for the quarter and six months ended June 30, 2026. The company remains a clinical-stage biopharmaceutical business focused on its Phase III Flamingo-01 trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, and continues to generate no revenue.
For the six months ended June 30, 2026, the company recorded a net loss of $9.6 million, compared with $6.5 million in the prior-year period, driven mainly by higher research and development and stock-based compensation expenses. Research and development spending rose to $8.8 million, while general and administrative expenses reached $1.0 million. Cash used in operations was $6.6 million.
Liquidity is supported primarily by equity raises. During the first half of 2026, Greenwich LifeSciences issued 379,762 shares via At The Market offerings for net proceeds of $9.3 million, increasing cash to $8.9 million as of June 30, 2026 and stockholders’ equity to $3.1 million. The company’s accumulated deficit was $96.7 million.
Management states that recurring losses and negative operating cash flows raise substantial doubt about the ability to continue as a going concern within one year, and notes dependence on additional capital. Management also identifies material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient systems and written procedures, and is developing a remediation plan. Director and insider share lock-ups have been extended through January 31, 2027, after which leak-out provisions will apply.
Greenwich LifeSciences, Inc. reported a net loss of $5.7 million for the quarter ended March 31, 2026, compared with $2.7 million a year earlier, as it continues developing its breast cancer immunotherapy GLSI-100 and expanding the Phase III Flamingo-01 trial.
Research and development spending rose to $5.2 million from $2.3 million, reflecting higher clinical trial costs, while general and administrative expenses were roughly flat at $0.5 million. The company had $10.5 million of cash on March 31, 2026, funded largely by equity sales through its at-the-market program.
Management states there is substantial doubt about the company’s ability to continue as a going concern within one year without additional capital. The filing also discloses material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient accounting systems.
Greenwich LifeSciences (GLSI) reported Q3 2025 results with no revenue and a net loss of $4,151,845 (basic and diluted loss per share $0.30). For the nine months ended September 30, net loss was $11,435,485 as R&D rose to $3,521,576 in Q3 and $9,630,604 year to date, reflecting clinical spend and stock-based compensation; G&A reached $653,066 in Q3 and $1,872,323 year to date.
Cash was $3,806,978 at September 30. The company raised capital via its ATM, issuing 621,674 shares for gross proceeds of $6,492,994 (net $6,308,784) year to date, plus 59,962 shares for gross $631,362 (net $612,420) after quarter end. In September, remaining underwriter warrants were exercised for $145,000. Shares outstanding were 13,794,577 at September 30 and 13,854,539 as of October 28.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and reported material weaknesses in internal controls. The Phase III Flamingo‑01 trial of GLSI‑100 continues as the core operating focus.